Abstract
The clinical and economic impacts of monitoring cardiac function in patients given doxorubicin have yet to be determined, especially in relation to patient age, cumulative doxorubicin dose, and the relative efficacies of doxorubicin-based vs alternative regimens. We developed a decision analysis model that includes these factors to estimate the incremental survival benefit and cost-effectiveness of using multiple gated acquisition scans to measure left-ventricular ejection fraction before and during doxorubicin chemotherapy. Probability distributions for the incidences of abnormal left-ventricular ejection fraction findings and congestive heart failure were derived from a retrospective review of 227 consecutive cases at The University of Michigan Medical Center and published findings. Multiple gated acquisition-scan monitoring minimally improved the probability of 5-year survival (<1.5% in the base–case scenario). For patients who received up to 350 mg m−2 of doxorubicin, multiple gated acquisition-scan screening had an incremental cost of $425402 per life saved for patients between the ages of 15–39. This incremental cost markedly decreased to $138191, for patients between the ages of 40–59, and to $86829 for patients older than 60 years. The small gain in 5-year survival probability secondary to multiple gated acquisition scan monitoring doubled for all age groups when the average cumulative dose for doxorubicin reached 500 mg m−2. Variations in the cure rate differences between the doxorubicin and alternative regimens had insignificant effects on the improvement in 5-year survival rates from multiple gated acquisition-scan screening. The use of multiple gated acquisition scans for pretreatment screening appears to be more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m−2 or less.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bennett JM, Andersen JW, Begg CB, Glick JH (1993) Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. Leuk Res 17: 825–832
Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 104: 739–746
Carrio I, Estorch M, Lopez-Pousa A (1996) Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 23: 359–364
Dracup K, Baker DW, Dunbar SB, Dacey RA, Brooks NH, Johnson JC, Oken C, Massie BM (1994) Management of heart failure. II. Counseling, education, and lifestyle modifications. JAMA 272: 1442–1446
Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ (1997) Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center. Cancer 80: 2176–2180
Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27: 53–68
Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press
Kleber FX, Niemoller L (1993) Long-term survival in the Munich Mild Heart Failure Trial (MHFT). Am J Cardiol 71: 1237–1239
Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349–1355
Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R (1999) Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology 117: 784–793
Paul SD, Kuntz KM, Eagle KA, Weinstein MC (1994) Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 154: 1143–1149
Radford JA, Crowther D, Rohatiner AZ, Ryder WD, Gupta RK, Oza A, Deakin DP, Arnott S, Wilkinson PM, James RD (1995) Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 13: 2379–2385
Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, Wackers FJTh, Zaret BL (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82: 1109–1118
Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47–58
Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH (1997) Economic analysis of a randomized clinical trial to compare filgrastim- mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 15: 5–10
Steinherz LJ, Yahalom J (1997) Toxicity. In Cancer: Principle and Practice of Oncology. Vincent T, Devita J, Hellman S, Steven AR (eds) p 2739 Philadelphia; New York: Lippincott-Raven
Stewart CF, Ratan MJ (1997) Anthracyclines and related compounds. In Cancer: Principle and Practice of Oncology. Vincent T, Devita J, Hellman S, Steven AR (eds) p 463 Philadelphia; New York: Lippincott-Raven
Stinnett AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen DJ, Williams LW, Goldman PA, Staiger DO, Hunink MGM, Tsevat J, Tosteson ANA, Goldman L (1996) The cost-effectiveness of dietary and pharmacologic therapy for cholestrol reduction in adults. In Cost-Effectiveness in Health and Medicine Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) p 364–385, New York: Oxford University Press
Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710–717
Acknowledgements
Portions of this manuscript were presented at the 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 1998.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shureiqi, I., Cantor, S., Lippman, S. et al. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer 86, 226–232 (2002). https://doi.org/10.1038/sj.bjc.6600037
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600037
Keywords
This article is cited by
-
Nuclear cardio-oncology: From its foundation to its future
Journal of Nuclear Cardiology (2020)
-
Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities
Supportive Care in Cancer (2011)
-
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Cardiovascular Toxicology (2007)
-
The effect of age on the early disposition of doxorubicin
Cancer Chemotherapy and Pharmacology (2003)